Galanthamine in Alzheimer's disease. A new alternative to tacrine?

CNS Drugs

Volumn 7, Issue 2, 1997, Pages 89-97

  Rainer, Michael ^a  

^a DANUBE HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

GALANTAMINE; TACRINE;

ALZHEIMER DISEASE; BRADYCARDIA; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; VERTIGO;

EID: 0031043364     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199707020-00001     Document Type: Review

References (56)

1. Fales HM, Giuffrida LD, Wildman WC. Alkaloids of the Amaryllidaceae. VIII. The structures of narcissamine, leucorine, pseudoleucorine and methlpseudoleucorine. J Am Chem Soc 1956; 78: 4145
2. Proskurnina NF, Yakovleva J. Alkaloids of Galanthus worownii. J Gen Chem USSR 1952; 22: 1899-902
3. Uyeo S, Kobayashi S. Pharm Bull Tokyo 1953; 1: 139
4. Boissier JR, Combes G, Pagny J. La galanthamine, puissant cholinergique naturel. Ann Pharm Fr 1960; 48: 888-900
5. Irwin RL, Smith HJ. Cholinesterase inhibition by galanthamine and lycoramine. Biochem Pharmacol 1960; 3: 147-8
6. Nesterenko LN. Influence exerted by galanthamine on the acetylcholinesterase activity of various regions of the brain. Farmakol Toksikol 1964; 28: 413-4
7. Pestel M. Une nouvelle médication de la myasthenie et des dystrophies neuro-musculaires: la nivaline. Presse Med 1961; 69: 182-3
8. Revelli U, Grasso E. Le traitement de la poliomyelite a la nivaline. Minerva Med 1962; 53: 881-4
9. Kilimov N. Trattamento della neuralgia del nervo trigemino. Cultura Medica 1961; 23: 313-22
10. Tsukanova VN. Galanthamine in the treatment of patients with cochlear neuritis and ganglionitis [in Russian]. Vestn Otorinolaringol 1967; 29 (3): 57-60
11. Stojanov EA. Clinical experiences with the new curare antidote galanthamine (nivalin). In: Mayrhofer O, editor. European trends in anaesthesiology: international anaesthesiology clinics. Boston: Brown & Co., 1965: 675-85
12. Cozanitis DA. Experiences with galanthamine hydrobromide as curare antagonist. Anaesthesia 1971; 20 (6): 226-9
13. Sedloev S, Georgiev I, Milev M. On the effect of Nivalin upon intestinal peristalsis. Acta Med (Sofia) 1964; 43 (1): 69-73
14. Cozanitis DA, Nuuttila K, Karhunen P, et al. Changes in cardiac rhythm with galanthamine hydrobromide. Anaesthesia 1973; 22: 457-9
15. Cozanitis DA, Toivakka H, Dessypris A. Electroencephalographic and blood chemistry responses to galanthamine hydrobromide in epileptic volunteers. Anaesthesia 1973; 22: 31-3
16. Cozanitis DA. Galanthamine hydrobromide versus neostigmine. Anaesthesia 1974; 29: 123-68
17. Cozanitis DA, Toivakka E. Study of galanthamine hydrobromide and atropine/neostigmine. Anaesthesia 1971; 20 (11): 416-21
18. Holl G, Straschill M, Thomsen T, et al. Effect of the cholines-terase inhibiting substance galanthamine on human EEG and visual evoked potentials. Electroencephalogr Clin Neurophysiol 1992; 82: 445-52
19. Riemann D, Gann H, Dressing H, et al. Influence of the cholinesterase inhibitor galanthamine hydrobromide on normal sleep. Psychiatry Res 1994; 51: 253-67
20. Tassonyi E, Labanez K, Vimláti L, et al. Postoperative apnoea following nívalin administration. Anaesthesia 1976; 25: 529-31
21. Cozanitis DA, Toivakka E. Treatment of respiratory depression with the anticholinesterase drug galanthamine hydrobromide. Anaesthesia 1974; 29: 581-4
22. Losev NA, Kamenetskii VK. Method of treating parkinsonism with metamizil in combination with galanthamine (clinico-experimental basis). Zh Nevropatol Psikhiatr 1985; 85 (3): 376-81
23. Becker RE, Moriearty P, Unni L. The second generation of cholinesterase inhibitors: clinical and pharmacological effects. In: Becker R, Giacobini E, editors. Cholinergic basis for Alzheimer therapy. Boston: Birkhauser, 1991: 263-96
24. Rainer M, Mucke H, Janoch P, et al. Galanthamine treatment in Alzheimer's disease: the identification of responders. Neuropsychopharmacology 1994; 10 No. 3, Pt 2: 2155
25. Giacobini E. The second generation of cholinesterase inhibitors: pharmacological aspects. In: Becker R, Giacobini E, editors. Cholinergic basis for Alzheimer's therapy. Boston: Birkhauser, 1991: 247-62
26. Bickel U, Thomsen T, Weber W et al. Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. Clin Pharmacol Ther 1991; 50: 420-8
27. Mihailova D, Yamboliev I, Dishovski C. Modeling of pharmacokinetic and pharmacodynamic behaviour of nivalin in anaesthetized cats. Methods Find Exp Clin Pharmacol 1985; 7 (11): 595-601
28. Westra P, Van Thiel MJS, Vermeer GA, et al. Pharmacokinetics of galanthamine (a long-acting anticholinesterase drug) in anaesthetized patients. Br J Anaesth 1986; 58: 1303-7
29. Mihailova D, Velkov M, Zhivkova Z. In vitro metabolism of galanthamine hydrobromide (Nivalin) by rat and rabbit liver homogenate. Eur J Drug Metab Pharmacokinet 1987; 12 (1): 25-30
30. Bickel U, Thomsen T, Fischer JP, et al. Galanthamine: pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice. Neuropharmacology 1991; 30 (5): 447-54
31. Thomsen T, Bickel U, Fischer JP, et al. Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans. Eur J Clin Pharmacol 1990; 39: 603-5
32. Berzewski H, Kewitz H, Davis B, et al. Galanthamine, a selective nontoxic centrally acting and reversible acetylcholinesterase inhibitor, for the treatment of SDAT [abstract]. XIXth Collegium Internationale Neuro-Psychopharmacologicum Congress: 1994 Jun 27-Jul 1; Washington, DC. Neuropsychopharmacology 1994; 10 (35; Pt 2): P-58-147
33. Mihailova D, Yamboliev I. Pharmacokinetics of galanthamine hydrobromide (Nivalin) following single intravenous and oral administration in rats. Pharmacology 1986; 32 (6): 301-6
34. Thomsen T, Kaden B, Fischer JP, et al. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine. Eur J Clin Chem Clin Biochem 1991; 29: 487-92
35. Pleul O, Rost L, Thomsen T, et al. Correlation between blood and tissue levels of tetrahydroaminoacridine, cholinesterase inhibition, and acetylcholine increase in the brain. In: Kewitz H, Thomsen T, Bickel U, editors. Pharmacological interventions on central cholinergic mechanisms in senile dementia (Alzheimer's disease). München: W. Zuckschwerdt, 1989: 292-7
36. Thomsen T, Kewitz H. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci 1990; 46: 1553-8
37. Thomsen T, Zendeh B, Fischer JP, et al. In vitro effects of various cholinesterase inhibitors on acetyl- and butyrylcholinesterase of healthy volunteers. Biochem Pharmacol 1991; 41 (1): 139-41
38. Cooper JR, Bloom FE, Roth RH. The biochemical basis of neuropharmacology. 5th ed. New York: Oxford University Press, 1986
39. Becker RE, Colliver J, Elble R, et al. Effects of metrifonate, a long-acting cholinesterase inhibitor, in Alzhemier disease: report of an open trial. Drug Dev Res 1990; 19: 425-34
40. Ravindran RS, Cummins DF, Pantazis KL. Unusual aspects of low levels of pseudocholinesterase in a pregnant patient. Anaesth Analg 1982; 61: 953-7
41. Wagstaff AJ, McTavish D. Tacrine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs Aging 1994; 4 (6): 510-40
42. Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271 (13): 992-8
43. Knapp MJ, Gracon SI, Davis CS, et al. Efficacy and safety of high-dose tacrine: a 30-week evaluation. Alzheimer Dis Assoc Disord 1994; 8 Suppl. 2: S22-31
44. Davis B. Method of treating Alzheimer's disease. US Patent 4 663 318 (1987 May 5)
45. Thomsen T, Kewitz H. Galanthamine treatment in senile dementia of Alzheimer's type: a case report. In: Kewitz H, Thomsen T, Bickel U, editors. Pharmacological interventions on central cholinergic mechanisms in senile dementia (Alzheimer's disease). München: W. Zuckschwerdt, 1989: 238-41
46. Sweeney JE, Höhmann CF, Moran TH, et al. A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice. Pharmacol Biochem Behav 1988; 31 (1): 141-7
47. Chaplygina SR, Il'iuchenok RLU. Effect of cholinergic substances in experimental amnesia [in Russian]. Zh Vyssh Nerv Deiat Im Pav 1976; 26: 1091-3
48. Rainer M, Mark T, Haushofer A. Galanthamine hydrobromide in the treatment of senile dementia of Alzheimer's type. In: Kewitz H, Thomsen T, Bickel U, editors. Pharmacological interventions on central cholinergic mechanisms in senile dementia (Alzheimer's disease). München: W. Zuckschwerdt, 1989: 233-7
49. Dal-Bianco P, Maly J, Wober C, et al. Galanthamine treatment in Alzheimer's disease. J Neural Transm 1991; Suppl. 33: 59-63
50. Wilcock GK, Scott M, Pearsall T, et al. Galanthamine and the treatment of Alzheimer's disease. Int J Geriatr Psychiatr 1993; 8 (9): 781-2
51. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed, rev. Washington, DC: American Psychiatry Association, 1987
52. Wilcock G, Wilkinson D. Galanthamine hydrobromide - interim results of a group comparative, placebo controlled study of efficacy and safety in patients with a diagnosis of senile dementia of the Alzheimer's type [abstract]. 5th International Conference on Alzheimer's Disease and Related Disorders: 1996 Jul; Osaka, abstract no. 578. Neurobiol Aging 1996; Suppl. Vol. 17 No. 4S: 144
53. Rainer M, Mucke H. Long-term efficacy of galanthamine in Alzheimer's disease: cognitive parameters after two and three years of treatment [abstract]. 8th Congress of the Association of European Psychiatrists: 1996 Jul 8-12; London
54. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271 (13): 985-91
55. McPherson S. Galanthamine: the new treatment of choice in Alzheimer's disease? Inpharma 1995; Sep 2 (1002): 3-5
56. Barton DHR, Kirby GW. The synthesis of galanthamine. Proc Chem Soc 1960: 392-3